Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?
- DOI
- 10.1016/j.ocarto.2022.100262
- Published
- 2022-09
- Container
- Osteoarthritis and Cartilage Open
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ocarto.2022.100262,
title = {Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?},
author = {M.A. Karsdal and J. Tambiah and M.C. Hochberg and C. Ladel and A.C. Bay-Jensen and L. Arendt-Nielsen and A. Mobasheri and V.B. Kraus},
year = {2022},
journal = {Osteoarthritis and Cartilage Open},
doi = {10.1016/j.ocarto.2022.100262},
url = {https://doi.org/10.1016/j.ocarto.2022.100262}
}RIS
TY - JOUR TI - Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status? AU - M.A. Karsdal AU - J. Tambiah AU - M.C. Hochberg AU - C. Ladel AU - A.C. Bay-Jensen AU - L. Arendt-Nielsen AU - A. Mobasheri AU - V.B. Kraus PY - 2022 JO - Osteoarthritis and Cartilage Open DO - 10.1016/j.ocarto.2022.100262 UR - https://doi.org/10.1016/j.ocarto.2022.100262 ER -
APA
Karsdal, M., Tambiah, J., Hochberg, M., Ladel, C., Bay-Jensen, A., Arendt-Nielsen, L., Mobasheri, A., & Kraus, V. (2022). Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?. Osteoarthritis and Cartilage Open. https://doi.org/10.1016/j.ocarto.2022.100262
Source records
- crossref · retrieved 2026-09-26T05:22:47.845Z